Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $145

Benzinga Newsdesk www.benzinga.com Positive 52.2%

Neg 0% Neu 0% Pos 52.2%

Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $120 to $145.